Date: 2016-04-18
Type of information: Opening of new premises
Compound:
Company: GSK (UK)
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Type agreement: opening of new premises
Action mechanism:
Disease: respiratory manufacturing facility in Ware
Details: * On April 18, 2016, GSK announced the opening of a £56 million state of the art manufacturing facility, creating 150 new jobs in the UK, in response to demand for GSK’s portfolio of respiratory medicines delivered by the innovative Ellipta® inhaler. The new 4500m2 facility is the latest expansion for Ellipta® manufacturing at Ware, with investment totalling over £100 million over the past five years. The new facility is expected to nearly double production of Ellipta® inhalers at Ware to at least 37 million per year by 2017, 95% of which will be exported. Since 2013, over 400 additional roles will have been created at the manufacturing site in Ware, bringing staff numbers to more than 1200. This includes over 30 apprentice and 50 graduate roles as part of GSK’s commitment to creating highly skilled roles for young people. GSK currently export Ellipta® inhalers from Ware to over 74 countries. GSK has nine manufacturing sites in the UK, four sites making active ingredients for medicines, three sites making finished medicine products, and two consumer healthcare sites.
Financial terms:
Latest news:
